Investment Rating - The investment rating for Shandong Expressway is "Buy" (maintained) [5] Core Views - The report emphasizes the strengthening of road asset scale and the realization of profit growth [5] - The company has shown steady performance in toll road operations, with revenue growth driven by completed upgrades and changes in the road network [7] - The management system's efficiency has improved, leading to enhanced profitability [7] Financial Summary - As of April 29, 2025, the closing price is 10.76 yuan, with a total market capitalization of 52,222.80 million yuan [3] - The company reported a revenue of 44.70 billion yuan in Q1 2025, a year-on-year decrease of 1.35%, while the net profit attributable to shareholders was 8.07 billion yuan, an increase of 4.85% [7] - The projected revenues for 2025-2027 are 28,471 million yuan, 29,067 million yuan, and 29,638 million yuan, respectively, with corresponding net profits of 3,216 million yuan, 3,378 million yuan, and 3,561 million yuan [6][8] Revenue and Profitability - The revenue from toll road operations in Q1 2025 was approximately 24.39 billion yuan, reflecting a year-on-year increase of 7.85% [7] - The gross profit margin for Q1 2025 was 39.18%, an increase of 3.54 percentage points year-on-year [7] - The company is expected to maintain a steady growth in net profit, with projections showing a slight increase in the coming years [7][8]

证券研究报告 交通运输 | 物流 非金融|公司点评报告 证券分析师 孙延 SAC：S1350524050003 sunyan01@huayuanstock.com 王惠武 SAC：S1350524060001 wanghuiwu@huayuanstock.com 曾智星 SAC：S1350524120008 zengzhixing@huayuanstock.com 张付哲 zhangfuzhe@huayuanstock.com 市场表现： | 收盘价（元） | | 6.14 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 一 年 内 高 最 低 | / | 8.29/5.46 | 最 | | | | | | （元） | | | | | | | | | 总市值（百万元） | | 13,308.23 | | | | | | | 流通市值（百万元） | | 13,091.45 | | | | | | | 总股本（百万股） | | 2,167.46 | | | | | | | 资产负债率（%） | | 67.35 | | | | | | ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage due to its leading position in interconnect chip solutions and strong growth prospects driven by industry trends and new product breakthroughs [5][6]. Core Views - The company is a global leader in data processing and interconnect chip design, with a comprehensive product matrix. It focuses on providing high-performance, low-power chip solutions for cloud computing and AI, maintaining a solid market position [5][10]. - In 2024, the company experienced significant business expansion, with a notable recovery in demand for its main products, particularly DDR5 memory interface chips, which surpassed DDR4 in shipment volume. The company achieved a revenue of 3.639 billion yuan, a year-on-year increase of 59.2%, and a net profit of 1.412 billion yuan, up 213.1% [5][40]. - The company is expected to benefit from the rapid growth of the AI server market, with predictions indicating that the AI server market value could reach 298 billion USD by 2025. The company is a key supplier of DDR5 memory interface chips and PCIe Retimer chips, which are crucial for this market [5][60]. Summary by Sections Market Performance - As of April 29, 2025, the company's closing price was 74.31 yuan, with a total market capitalization of 85,069.29 million yuan and a debt-to-asset ratio of 5.72% [3]. Financial Performance - The company reported a revenue of 12.22 billion yuan in Q1 2025, a year-on-year increase of approximately 65.78%, with a net profit of 5.25 billion yuan, up 135.14% [45]. - The revenue for 2024 was 36.39 billion yuan, with interconnect chip revenue reaching 33.49 billion yuan, a year-on-year growth of 53.31% [40]. Product Lines - The company has two main product lines: interconnect chips and the Zindai® server platform. The interconnect chip line includes memory interface chips, PCIe Retimer chips, and clock chips, while the server platform includes Zindai® CPUs and memory modules [5][14]. - The company has successfully launched several high-performance chips, including MRCD/MDB and CKD chips, which are expected to drive future revenue growth [26][40]. Growth Drivers - The company is actively expanding its business layout and investing in technology innovation, with a focus on high-level R&D investment. It aims to enhance its core technology and product applications, which are expected to drive long-term revenue and profit growth [5][10]. - The global server market is projected to grow significantly, with the AI server market expected to reach 298 billion USD by 2025, providing a favorable environment for the company's product demand [60][64]. Profit Forecast - The company is projected to achieve net profits of 21.01 billion yuan, 29.53 billion yuan, and 38.31 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding growth rates of 48.82%, 40.55%, and 29.74% [8][10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The oil transportation industry is facing short-term pressure on performance, but the OPEC+ production increase is favorable for the oil transportation market [6] Financial Performance Summary - Revenue projections for the company are as follows: - 2023: 22,091 million RMB - 2024: 23,244 million RMB (growth of 5.22%) - 2025E: 25,911 million RMB (growth of 11.48%) - 2026E: 27,856 million RMB (growth of 7.51%) - 2027E: 28,891 million RMB (growth of 3.72%) [7] - Net profit attributable to shareholders is projected as: - 2023: 3,351 million RMB - 2024: 4,037 million RMB (growth of 20.47%) - 2025E: 5,035 million RMB (growth of 24.73%) - 2026E: 6,412 million RMB (growth of 27.36%) - 2027E: 7,020 million RMB (growth of 9.49%) [7] - Earnings per share (EPS) forecast: - 2023: 0.70 RMB - 2024: 0.85 RMB - 2025E: 1.06 RMB - 2026E: 1.34 RMB - 2027E: 1.47 RMB [7] Key Financial Ratios - Return on Equity (ROE) is expected to improve: - 2023: 9.74% - 2024: 11.25% - 2025E: 12.95% - 2026E: 15.00% - 2027E: 14.95% [7] - Price-to-Earnings (P/E) ratio forecast: - 2024: 12.34 - 2025E: 9.89 - 2026E: 7.77 - 2027E: 7.09 [7] Market Data - Closing price as of April 29, 2025: 10.44 RMB - Market capitalization: 49,806.91 million RMB - Total shares outstanding: 4,770.78 million [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to see significant growth in its innovative segment, particularly with the upcoming realization of a major product for gout treatment [5][6] - The projected net profit for the company from 2025 to 2027 is estimated to be 200 million, 270 million, and 330 million RMB respectively, with year-on-year growth rates of 136.2%, 37.2%, and 22.4% [6] Financial Performance Summary - The company reported a revenue of 1.45 billion RMB in 2024, a decrease of 42.07% year-on-year, and a net loss of 540 million RMB, a decline of 392.52% year-on-year [8] - For Q1 2025, the revenue was 377 million RMB, down 39.48% year-on-year, with a net profit of 57 million RMB, a decrease of 43.70% year-on-year [8] - The company has a total market capitalization of approximately 17.7 billion RMB and a circulating market capitalization of about 16.36 billion RMB [3] Business Segments - In 2024, the children's medicine segment generated revenue of 936 million RMB, while the chronic disease medicine segment brought in 370 million RMB [8] - The company has 26 registered children's medicine products covering over 70% of childhood diseases [8] Research and Development - The company is advancing its AR882 product, which has shown promising results in reducing uric acid levels and dissolving gout stones, indicating a potential competitive edge in the market [8] - The company has received several new product registrations in the chronic disease segment, enhancing its product portfolio [8] Financial Projections - The projected revenue for 2025 is 1.82 billion RMB, with a year-on-year growth rate of 25.31% [9] - The estimated net profit for 2025 is 195 million RMB, with a significant recovery from the previous year's loss [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - Short-term profitability is under pressure, but overseas expansion opens new opportunities [6] - The company has a strong order backlog, which supports future revenue growth despite current performance challenges [8] Financial Performance - In Q1 2025, the company achieved revenue of 248.564 billion yuan, a year-on-year decrease of 6.21%, and a net profit attributable to shareholders of 6.025 billion yuan, down 19.46% year-on-year [8] - The company’s gross margin for Q1 2025 was 8.46%, a decrease of 0.13 percentage points year-on-year [8] - The company’s total uncompleted contract amount reached 7.234 trillion yuan, an increase of 5.1% compared to the end of the previous year, indicating a solid order book [8] Business Segments - Revenue from infrastructure construction, design consulting, equipment manufacturing, and real estate development for 2024 was 216.796 billion, 4.670 billion, 6.246 billion, and 6.671 billion yuan respectively, with year-on-year changes of -7.99%, -2.21%, -5.77%, and +59.48% [8] - The company signed new contracts worth 560.1 billion yuan in Q1 2025, a year-on-year decrease of 9.9%, with domestic contracts down 13.6% and overseas contracts up 33.4% [8] Profitability and Valuation - The company’s projected net profit for 2025-2027 is 28.7 billion, 29.7 billion, and 30.9 billion yuan respectively, with year-on-year growth rates of +2.88%, +3.70%, and +3.94% [8] - The current price-to-earnings ratio (P/E) is projected to be 4.78, 4.61, and 4.43 for 2025, 2026, and 2027 respectively [8]

证券研究报告 建筑装饰 | 基础建设 非金融|公司点评报告 hyzqdatemark 2025 年 04 月 30 日 证券分析师 王彬鹏 SAC：S1350524090001 wangbinpeng@huayuanstock.com 戴铭余 SAC：S1350524060003 daimingyu@huayuanstock.com 郦悦轩 SAC：S1350524080001 liyuexuan@huayuanstock.com 唐志玮 tangzhiwei@huayuanstock.com 林高凡 lingaofan@huayuanstock.com | 基本数据 | 29 | | | | 2025 | 年 | 04 | | 日 | 月 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | | 8.91 | | | | | 一 年 / 低 | | 最 | 高 | 内 | | | | 9.12/5.19 | | | 最 | | （元） | | | | | | | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The domestic production of "Hewei Zhengchang Wan" is imminent, and the clinical progress of the innovative drug for vitiligo is steady [5] - The company reported a revenue of 721 million yuan for 2024, a decrease of 5.23% year-on-year, and a net profit of 108 million yuan, down 32.45% year-on-year [7] - The company expects significant improvement in profitability following the domestic launch of gastrointestinal medications [7] Financial Performance Summary - Revenue projections for the company are as follows: 2023: 761 million yuan, 2024: 721 million yuan, 2025E: 902 million yuan, 2026E: 1,083 million yuan, 2027E: 1,296 million yuan [6] - The expected growth rates for revenue are -2.90% in 2023, -5.23% in 2024, 25.15% in 2025, 20.06% in 2026, and 19.60% in 2027 [6] - The projected net profit for 2025 is 176 million yuan, with a year-on-year growth of 62.37% [6] - The earnings per share (EPS) are forecasted to be 0.41 yuan in 2025, 0.56 yuan in 2026, and 0.71 yuan in 2027 [6] Business Segmentation - In 2024, the revenue breakdown is as follows: gastrointestinal medications: 206 million yuan (up 1.04% year-on-year), ophthalmic medications: 185 million yuan (up 0.13%), sexual health: 178 million yuan (down 20.87%), traditional Chinese medicine and external medications: 95 million yuan (down 10.03%) [7] - The company has made progress in its R&D pipeline, with the II phase clinical trial for CKBA ointment for vitiligo fully enrolled [7] - The company has received acceptance for the domestic listing application of "Hewei Zhengchang Wan" and is progressing with other innovative drugs [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company, Guoyao Yizhi, reported a revenue of 18.29 billion yuan in Q1 2025, a year-on-year decrease of 4.2%, and a net profit attributable to shareholders of 330 million yuan, down 15.6% year-on-year [5] - The distribution segment's revenue in Q1 2025 was 13.59 billion yuan, a decline of 2.6% year-on-year, while the retail segment generated 4.98 billion yuan, down 7.5% year-on-year, but turned profitable compared to previous quarters [8] - The company is expected to see improvements in profitability throughout 2025, with projected net profits of 1.33 billion yuan, 1.50 billion yuan, and 1.67 billion yuan for 2025, 2026, and 2027 respectively, indicating growth rates of 107.1%, 12.5%, and 11.7% [8] Financial Summary - As of April 29, 2025, the company's closing price was 24.53 yuan, with a total market capitalization of 13.65 billion yuan and a circulating market capitalization of 13.48 billion yuan [3] - The company's total assets are projected to grow from 50.08 billion yuan in 2025E to 56.78 billion yuan in 2027E, while total liabilities are expected to increase from 28.07 billion yuan to 31.76 billion yuan over the same period [9] - The company's return on equity (ROE) is forecasted to improve from 3.64% in 2024 to 7.91% in 2027 [7]

证券研究报告 医药生物 | 生物制品 非金融|公司点评报告 hyzqdatemark 2025 年 04 月 30 日 证券分析师 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 李强 SAC：S1350524040001 liqiang01@huayuanstock.com 市场表现： | 基本数据 | | | 2025 | 年 | 04 | 月 | 29 | 日 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | 22.04 | | | | 一 年 内 高 / 低 | 最 | 最 | | | | | | | 30.48/19.46 | | （元） | | | | | | | | | | | 总市值（百万元） | | | | | | | 16,112.89 | | | | 流通市值（百万元） | | | | | | | 15,933.44 | | | | 总股本（百万股） | | | | | | | 731.07 | | | | 资产 ...